arrow
E

Ettore D'Argento

catholic university of the sacred heart
H指数:23
被引数:1,703

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy

更正:卡马替尼用于治疗METex14跳读的非小细胞肺癌:意大利接受同情用药治疗患者的真实世界数据回顾性分析

2025-12-180
OAAI
Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy

卡马替尼治疗METex14跳读非小细胞肺癌:意大利接受同情用药治疗患者真实世界数据的回顾性分析

2025-11-180
OAAI
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study

PD-L1低表达转移性非小细胞肺癌一线化疗联合免疫治疗方案的疗效与安全性:一项意大利观察性研究的结果

2025-07-120
OAAI
Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics

接受新辅助治疗和手术治疗的临床III期NSCLC患者: 淋巴结特征的预后作用

2022-11-014
OAAI
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer

解开有丝分裂纺锤体: 肺癌中的极光激酶抑制剂的重点

2022-10-279
OAAI
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures

针对晚期非小细胞肺癌的KRAS复兴: 旧失败后的新机遇

2021-12-232
OAAI
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors

PTEN丢失是接受酪氨酸激酶抑制剂的EGFR突变晚期非小细胞肺癌患者肿瘤异质性和不良预后的预测指标

2021-07-0114
PRE
Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

在一项大型多中心真实世界研究中接受一线单药pembrolizumab治疗的PD-L1表达> 50% 的NSCLC患者的进展后结局

2021-05-0120
OAAI
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

抗生素治疗和其他药物对一线pembrolizumab与细胞毒性化疗治疗的非小细胞肺癌患者肿瘤学结局的差异影响

2021-04-0797
OAAI
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
2021-04-0144
OAAI
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

在PD-L1表达 ≥ 50% 的NSCLC患者的大型真实队列中,派姆单抗的免疫相关不良事件及其与临床结局的关系

2020-11-0163
OAAI
Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer

寡进展型EGFR突变非小细胞肺癌中酪氨酸激酶抑制剂与放疗相关的进展后生存结果

2019-11-1113
PREAI